Genomma Lab Internacional
Logotype for Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional (LABB) investor relations material

Genomma Lab Internacional Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Genomma Lab Internacional S.A.B. de C.V.
Q3 2026 earnings summary22 Oct, 2026

Executive summary

  • Q3 net sales rose 1.3% YoY to MXN 4,497.6m as Latin America growth and Mexico’s continued recovery offset a steep U.S. decline.

  • Mexico sell-out returned to growth and market share held or improved across business units; new products supported sell-out gains among customers carrying them.

  • Net income increased 18.6%, supported by lower financing costs and a favorable, non-recurring FX result; promotional and commercial investment pressured margins.

Financial highlights

  • Q3 net sales were MXN 4,497.6m, up 1.3% YoY; gross profit fell 2.6% to MXN 2,762.1m and gross margin declined to 61.4% from 63.9%.

  • Operating income fell 10.8% to MXN 863.6m; EBITDA declined 10.3% to MXN 944.9m, with margin at 21.0% versus 23.7%.

  • Net income rose 18.6% to MXN 514.9m; EPS increased 18.6% to MXN 0.51.

  • 9M net sales declined 3.2% to MXN 13,085.3m and EBITDA fell 11.0% to MXN 2,859.8m, while net income rose 7.5% to MXN 1,384.1m.

  • Excluding IAS 29 and IAS 21 effects, Q3 net sales declined 6.2%, EBITDA fell 18.8%, and net income increased 20.2% YoY.

Outlook and guidance

  • Q4 2026 cash conversion cycle expected to decline to ~140 days as Mexican winter inventory sells through and Argentina’s non-cash accounting effect normalizes.

  • Brazil sell-in expected to normalize in Q1 2027 after customer inventory reductions ahead of the consumption tax reform.

  • U.S. recovery expected to be gradual; commercial footprint and distribution model are being realigned to stabilize performance.

  • Q4 2026 and Q1 2027 Cough & Cold launches planned; December 3 Investor Day in New York to present strategy, operating model, execution commitments, and an AI platform.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Genomma Lab Internacional earnings date

Logotype for Genomma Lab Internacional S.A.B. de C.V.
Investor Day 20263 Dec, 2026
Genomma Lab Internacional
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Genomma Lab Internacional earnings date

Logotype for Genomma Lab Internacional S.A.B. de C.V.
Investor Day 20263 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Genomma Lab Internacional S.A.B. de C.V. specializes in pharmaceutical and personal care products, with a growing international presence. The company is recognized for developing, selling, and marketing a wide array of premium branded products, many of which hold leading positions in their respective categories in terms of sales and market share. Genomma Lab is distinguished by its successful new product development process, consumer-oriented marketing strategies, extensive retail distribution network, and a low-cost, highly flexible operating model. The company is headquartered in Mexico City, Mexico, and its shares are listed on the BMV.